Home/Filings/4/0001209191-22-050508
4//SEC Filing

Lang Daniel 4

Accession 0001209191-22-050508

CIK 0001300699other

Filed

Sep 18, 8:00 PM ET

Accepted

Sep 19, 4:19 PM ET

Size

13.0 KB

Accession

0001209191-22-050508

Insider Transaction Report

Form 4
Period: 2022-09-16
Lang Daniel
Pres Cell Therapy, VP Corp Dev
Transactions
  • Tax Payment

    Common Stock

    2022-09-16$0.41/sh4,323$1,76681,590 total
  • Exercise/Conversion

    Common Stock

    2022-09-16+12,50085,913 total
  • Exercise/Conversion

    Restricted Stock Units

    2022-09-1612,50037,500 total
    Common Stock (12,500 underlying)
Holdings
  • Stock Option (Right to Buy)

    Exercise: $10.25Exp: 2030-08-27Common Stock (40,000 underlying)
    40,000
  • Stock Option (Right to Buy)

    Exercise: $0.67Exp: 2032-07-20Common Stock (200,000 underlying)
    200,000
  • Stock Option (Right to Buy)

    Exercise: $2.77Exp: 2031-09-16Common Stock (50,000 underlying)
    50,000
Footnotes (6)
  • [F1]Each restricted stock unit represents a contingent right to receive one share of stock.
  • [F2]Includes 30,000 shares subject to a restricted stock award vesting in four equal annual installments beginning on August 26, 2020.
  • [F3]This option vests in four equal annual installments beginning on August 27, 2021.
  • [F4]This option vests in four equal annual installments beginning on September 16, 2022.
  • [F5]The restricted stock units vest in four equal annual installments beginning on September 16, 2022.
  • [F6]This option vests in four equal annual installments beginning on July 20, 2023.

Issuer

Athenex, Inc.

CIK 0001300699

Entity typeother

Related Parties

1
  • filerCIK 0001895384

Filing Metadata

Form type
4
Filed
Sep 18, 8:00 PM ET
Accepted
Sep 19, 4:19 PM ET
Size
13.0 KB